MorphoSys and Incyte's Minjuvi (tafasitamab) + Lenalidomide Receive EC's Approval for the Treatment of R/R DLBCL
Shots:
- The conditional approval is based on the P-II L-MIND study evaluating the safety and efficacy of tafasitamab + lenalidomide in patients with r/r DLBCL who are not eligible for ASCT
- Results: ORR (56.8%); CR rate (39.5%); PR rate (17.3%) as assessed by an IRC; m-DoR (43.9mos.) after a minimum follow up of 35mos.
- Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAb & is co-marketed by both companies under the brand name Monjuvi in the US & Minjuvi in the EU. Additionally- both companies share global development rights for the therapy
| Ref: Incyte | Image: Morphosys US
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com